Abstract
The discovery of small molecule melanin concentrating hormone receptor (MHCr1) antagonists as novel therapeutic agents has been widely pursued across the pharmaceutical industry. While multiple chemotypes of small molecule MCHr1 antagonists have been identified and shown to induce weight loss in rodent models of obesity, many of these lead compounds have been found to cross react with the hERG channel. This review describes efforts that led to the identification of two sub-series of MCHr1 antagonists with low affinity for the hERG channel. Ultimately, however, the modifications introduced to thwart hERG channel activity resulted in lead compounds with sub-optimal CNS behavior.
Keywords: MCHr1 antagonist, hERG channel
Current Topics in Medicinal Chemistry
Title: Lead Optimization of Melanin Concentrating Hormone Receptor 1 Antagonists with low hERG Channel Activity
Volume: 8 Issue: 13
Author(s): Andrew S. Judd, Andrew J. Souers and Philip R. Kym
Affiliation:
Keywords: MCHr1 antagonist, hERG channel
Abstract: The discovery of small molecule melanin concentrating hormone receptor (MHCr1) antagonists as novel therapeutic agents has been widely pursued across the pharmaceutical industry. While multiple chemotypes of small molecule MCHr1 antagonists have been identified and shown to induce weight loss in rodent models of obesity, many of these lead compounds have been found to cross react with the hERG channel. This review describes efforts that led to the identification of two sub-series of MCHr1 antagonists with low affinity for the hERG channel. Ultimately, however, the modifications introduced to thwart hERG channel activity resulted in lead compounds with sub-optimal CNS behavior.
Export Options
About this article
Cite this article as:
Judd S. Andrew, Souers J. Andrew and Kym R. Philip, Lead Optimization of Melanin Concentrating Hormone Receptor 1 Antagonists with low hERG Channel Activity, Current Topics in Medicinal Chemistry 2008; 8 (13) . https://dx.doi.org/10.2174/156802608785700052
DOI https://dx.doi.org/10.2174/156802608785700052 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Indications, Implications and Applications of Renal Denervation. Have we Discovered Something new?
Current Hypertension Reviews Effects of Anesthetics on Mitochondrial Signaling and Function
Current Drug Safety Novel Ventricular Fibrillation/Tachycardia Detection Algorithms Used for Automated External Defibrillators
Recent Patents on Engineering Hydroxychloroquine and Azithromycin Combination in the Management of COVID-19 Infection: Safety and Effectiveness Challenges
Current Drug Safety Wharton's Jelly Mesenchymal Stem Cell Response on Chitosan-graft-poly (ε-caprolactone) Copolymer for Myocardium Tissue Engineering
Current Pharmaceutical Design Preface [Hot Topic: Antihypertensive Drugs (Executive Editor : Gregory Y.H. Lip)].
Current Pharmaceutical Design The Impact of Ancillary Subunits on Small-Molecule Interactions with Voltage-Gated Potassium Channels
Current Pharmaceutical Design Pharmacological Prevention of Peri-, and Post-Procedural Myocardial Injury in Percutaneous Coronary Intervention
Current Cardiology Reviews Best Practice for Atrial Fibrillation Patient Education
Current Pharmaceutical Design Editorial: Cocaine and Cerebral Small Vessel: Is it a Negative Factor for Intravenous Thrombolysis?
Current Vascular Pharmacology Heart Disease in Patients with HIV/AIDS-An Emerging Clinical Problem
Current Cardiology Reviews Lipid-Induced Modulation of Protective Signalling Pathways in Cardiovascular Disease: The Role of High Density Lipoproteins
Current Signal Transduction Therapy Selective Pharmacological Inhibition of the Pacemaker Channel Isoforms (HCN1-4) as New Possible Therapeutical Targets
Current Medicinal Chemistry Anderson-Fabry Disease: A Multiorgan Disease
Current Pharmaceutical Design Clinical Management of the Cardiovascular Failure in Sepsis
Current Vascular Pharmacology Multifaceted Individualities in Pharmacological Treatments of Obesity
Current Clinical Pharmacology Advances in Peptide Pharmaceuticals
Current Pharmaceutical Biotechnology Side Effects of AAS Abuse: An Overview
Mini-Reviews in Medicinal Chemistry Does Pharmacological Therapy Still Play a Role in Preventing Sudden Death in Surgically Treated Tetralogy of Fallot?
Mini-Reviews in Medicinal Chemistry An Emerging Antiarrhythmic Target: Late Sodium Current
Current Pharmaceutical Design